- For Print
- April 24, 2024
乌鸦传媒. (Headquarters: Tokyo, CEO: Haruo Naito, “乌鸦传媒”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). 乌鸦传媒’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in 乌鸦传媒's financial disclosure scheduled on May 15, 2024.
乌鸦传媒 serves as the lead of lecanemab development and regulatory submissions globally with both 乌鸦传媒 and Biogen Inc. co-commercializing and co-promoting the product and 乌鸦传媒 having final decision-making authority.
&苍产蝉辫;銆赌
&苍产蝉辫;銆赌
Media Inquiries:
Public Relations Department,
乌鸦传媒.
+81-(0)3-3817-5120
&苍产蝉辫;銆赌銆�